Arthur M Feldman

List of Publications by Year
in descending order

80 papers	4,044 citations	147801 31 h-index	118850 62 g-index
81 all docs	81 docs citations	81 times ranked	4809 citing authors

#	Article	IF	Citations
1	Targeted Anticytokine Therapy in Patients With Chronic Heart Failure. Circulation, 2004, 109, 1594-1602.	1.6	1,062
2	Effects of Vesnarinone on Morbidity and Mortality in Patients with Heart Failure. New England Journal of Medicine, 1993, 329, 149-155.	27.0	484
3	Results of Targeted Antiâ€"Tumor Necrosis Factor Therapy With Etanercept (ENBREL) in Patients With Advanced Heart Failure. Circulation, 2001, 103, 1044-1047.	1.6	358
4	Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Journal of the American College of Cardiology, 2004, 44, 2019-2026.	2.8	149
5	Paroxetine-mediated GRK2 inhibition reverses cardiac dysfunction and remodeling after myocardial infarction. Science Translational Medicine, 2015, 7, 277ra31.	12.4	126
6	Aldosterone Synthase Promoter Polymorphism Predicts Outcome in African Americans With Heart Failure. Journal of the American College of Cardiology, 2006, 48, 1277-1282.	2.8	89
7	BAG3: a new player in the heart failure paradigm. Heart Failure Reviews, 2015, 20, 423-434.	3.9	79
8	TRPM2 Channels Protect against Cardiac Ischemia-Reperfusion Injury. Journal of Biological Chemistry, 2014, 289, 7615-7629.	3.4	78
9	Endothelial Nitric Oxide Synthase (NOS3) Polymorphisms in African Americans With Heart Failure: Results From the A-HeFT Trial. Journal of Cardiac Failure, 2009, 15, 191-198.	1.7	69
10	Decreased Levels of BAG3 in a Family With a Rare Variant and in Idiopathic Dilated Cardiomyopathy. Journal of Cellular Physiology, 2014, 229, 1697-1702.	4.1	68
11	The second member of transient receptor potential-melastatin channel family protects hearts from ischemia-reperfusion injury. American Journal of Physiology - Heart and Circulatory Physiology, 2013, 304, H1010-H1022.	3.2	62
12	Cardiomyocyte contractile impairment in heart failure results from reduced BAG3-mediated sarcomeric protein turnover. Nature Communications, 2021, 12, 2942.	12.8	62
13	The National Institutes of Health Physician-Scientist Workforce Working Group Report: A Roadmap for Preserving the Physician-Scientist. Clinical and Translational Science, 2014, 7, 289-290.	3.1	60
14	Evidence for the Role of BAG3 in Mitochondrial Quality Control in Cardiomyocytes. Journal of Cellular Physiology, 2017, 232, 797-805.	4.1	60
15	Ca²⁺entry via Trpm2 is essential for cardiac myocyte bioenergetics maintenance. American Journal of Physiology - Heart and Circulatory Physiology, 2015, 308, H637-H650.	3.2	57
16	Association of Variants in <i>BAG3</i> With Cardiomyopathy Outcomes in African American Individuals. JAMA Cardiology, 2018, 3, 929.	6.1	57
17	BAG3 regulates contractility and Ca2+ homeostasis in adult mouse ventricular myocytes. Journal of Molecular and Cellular Cardiology, 2016, 92, 10-20.	1.9	56
18	GRP78 Interacting Partner Bag5 Responds to ER Stress and Protects Cardiomyocytes From ER Stressâ€Induced Apoptosis. Journal of Cellular Biochemistry, 2016, 117, 1813-1821.	2.6	48

#	Article	IF	Citations
19	Current Landscape of Heart Failure Gene Therapy. Journal of the American Heart Association, 2019, 8, e012239.	3.7	45
20	Regulation of cardiac myocyte contractility by phospholemman: Na+/Ca2+ exchange versus Na+-K+-ATPase. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 295, H1615-H1625.	3.2	44
21	Induced overexpression of Na⁺/Ca²⁺ exchanger transgene: altered myocyte contractility, [Ca²⁺]_i transients, SR Ca²⁺ contents, and action potential duration. American Journal of Physiology - Heart and Circulatory Physiology, 2009, 297, H590-H601.	3.2	44
22	Controlled and Cardiac-Restricted Overexpression of the Arginine Vasopressin V1A Receptor Causes Reversible Left Ventricular Dysfunction Through GÎ± _q -Mediated Cell Signaling. Circulation, 2011, 124, 572-581.	1.6	44
23	G-Protein Beta-3 Subunit Genotype Predicts Enhanced Benefit of Fixed-Dose Isosorbide Dinitrate and Hydralazine. JACC: Heart Failure, 2014, 2, 551-557.	4.1	40
24	The Multifunctional Protein BAG3. JACC Basic To Translational Science, 2018, 3, 122-131.	4.1	40
25	Bcl-2â€“associated athanogene 3 protects the heart from ischemia/reperfusion injury. JCI Insight, 2016, 1, e90931.	5.0	40
26	Valsartan/Sacubitril for Heart Failure. JAMA - Journal of the American Medical Association, 2016, 315, 25.	7.4	38
27	Arginine vasopressin receptor signaling and functional outcomes in heart failure. Cellular Signalling, 2016, 28, 224-233.	3.6	37
28	miR-146a targets <i>c-Fos</i> expression in human cardiac cells. DMM Disease Models and Mechanisms, 2015, 8, 1081-91.	2.4	35
29	Î²-Adrenergic Receptorâ€“Mediated Cardiac Contractility Is Inhibited via Vasopressin Type 1A-Receptorâ€“Dependent Signaling. Circulation, 2014, 130, 1800-1811.	1.6	34
30	Therapeutic targeting of BAG3: considering its complexity in cancer and heart disease. Journal of Clinical Investigation, 2021, 131, .	8.2	34
31	A common variant alters SCN5Aâ€“miR-24 interaction and associates with heart failure mortality. Journal of Clinical Investigation, 2018, 128, 1154-1163.	8.2	34
32	Regulation of in vivo cardiac contractility by phospholemman: role of Na+/Ca2+ exchange. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 300, H859-H868.	3.2	33
33	Adeno-Associated Virus Serotype 9â€“Driven Expression of BAG3 Improves LeftÂVentricular Function in Murine Hearts With Left Ventricular Dysfunction Secondary to a Myocardial Infarction. JACC Basic To Translational Science, 2016, 1, 647-656.	4.1	32
34	Haploâ€insufficiency of Bcl2â€associated athanogene 3 in mice results in progressive left ventricular dysfunction, Î²â€adrenergic insensitivity, and increased apoptosis. Journal of Cellular Physiology, 2018, 233, 6319-6326.	4.1	32
35	Phospholemman and Î²-adrenergic stimulation in the heart. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 298, H807-H815.	3.2	31
36	Prognostic Significance of Biomarkers in Predicting Outcome in Patients With Coronary Artery Disease and Left Ventricular Dysfunction. Circulation: Heart Failure, 2013, 6, 461-472.	3.9	28

#	Article	IF	Citations
37	Rationale and Design of the Enoximone Clinical Trials Program. Journal of Cardiac Failure, 2005, 11, 659-669.	1.7	26
38	Constitutive overexpression of phosphomimetic phospholemman S68E mutant results in arrhythmias, early mortality, and heart failure: potential involvement of Na⁺/Ca²⁺ exchanger. American Journal of Physiology - Heart and Circulatory Physiology, 2012, 302, H770-H781.	3.2	26
39	Increased Vasopressin 1A Receptor Expression in Failing Human Hearts. Journal of the American College of Cardiology, 2014, 63, 375-376.	2.8	21
40	Sudden Cardiac Death in Patients With Ischemic Heart Failure Undergoing Coronary Artery Bypass Grafting. Circulation, 2017, 135, 1136-1144.	1.6	21
41	Coordinated Regulation of Cardiac Na+/Ca2+ Exchanger and Na+-K+-ATPase by Phospholemman (FXYD1). Advances in Experimental Medicine and Biology, 2013, 961, 175-190.	1.6	20
42	Benchâ€toâ€Bedside; Clinical and Translational Research; Personalized Medicine; Precision Medicineâ€"What's in a Name?. Clinical and Translational Science, 2015, 8, 171-173.	3.1	20
43	Cardiac Dysfunction in HIVâ€1 Transgenic Mouse: Role of Stress and BAG3. Clinical and Translational Science, 2015, 8, 305-310.	3.1	20
44	Regulation of L-type calcium channel by phospholemman in cardiac myocytes. Journal of Molecular and Cellular Cardiology, 2015, 84, 104-111.	1.9	18
45	Induced Overexpression of Na+/Ca2+ Exchanger Does Not Aggravate Myocardial Dysfunction Induced by Transverse Aortic Constriction. Journal of Cardiac Failure, 2013, 19, 60-70.	1.7	16
46	Genetic Testing for Inherited Cardiac Diseases in Underserved Populations of Non-European Ancestry. JAMA Cardiology, 2018, 3, 273.	6.1	14
47	Mitochondrial dysfunction in human immunodeficiency virusâ€1 transgenic mouse cardiac myocytes. Journal of Cellular Physiology, 2019, 234, 4432-4444.	4.1	14
48	Role of Bcl2-associated Athanogene 3 in Turnover of Gap Junction Protein, Connexin 43, in Neonatal Cardiomyocytes. Scientific Reports, 2019, 9, 7658.	3.3	13
49	Trpm2 enhances physiological bioenergetics and protects against pathological oxidative cardiac injury: Role of Pyk2 phosphorylation. Journal of Cellular Physiology, 2019, 234, 15048-15060.	4.1	10
50	The Addition of a Defibrillator toÂResynchronization Therapy DecreasesÂMortality in Patients With Nonischemic Cardiomyopathy. JACC: Heart Failure, 2021, 9, 439-449.	4.1	10
51	A Metricâ€Based System for Evaluating the Productivity of Preclinical Faculty at an Academic Medical Center in the Era of Clinical and Translational Science. Clinical and Translational Science, 2015, 8, 357-361.	3.1	9
52	Neprilysin Inhibition in the TimeÂofÂPrecision Medicine âˆ—. JACC: Heart Failure, 2016, 4, 409-414.	4.1	9
53	Precision Medicine for Heart Failure. Circulation: Heart Failure, 2017, 10, .	3.9	9
54	American medical education at a crossroads. Science Translational Medicine, 2015, 7, 285fs17.	12.4	8

#	Article	IF	Citations
55	Lamin B is a target for selective nuclear PQC by BAG3: implication for nuclear envelopathies. Cell Death and Disease, 2019, 10, 23.	6.3	8
56	Vasopressin Antagonists for Patients With Acute Heart Failure: Interpreting New Clinical and Translational Data. Clinical Pharmacology and Therapeutics, 2014, 95, 373-375.	4.7	7
57	To Breastfeed or Not to Breastfeed With Peripartum Cardiomyopathy. JACC Basic To Translational Science, 2019, 4, 301-303.	4.1	7
58	Whole transcriptome microarrays identify long non-coding RNAs associated with cardiac hypertrophy. Genomics Data, 2015, 5, 68-71.	1.3	6
59	Vasopressin typeÂ1A receptor deletion enhances cardiac contractility, Î²-adrenergic receptor sensitivity and acute cardiac injury-induced dysfunction. Clinical Science, 2016, 130, 2017-2027.	4.3	6
60	Incorporating Clinical and Translational Science into the Undergraduate Medical Education Curriculum. Clinical and Translational Science, 2015, 8, 267-267.	3.1	5
61	Novel BAG3 Variants in African American Patients With Cardiomyopathy: Reduced Î²-Adrenergic Responsiveness in Excitationâ€"Contraction. Journal of Cardiac Failure, 2020, 26, 1075-1085.	1.7	5
62	Genetic Variants Are Not Associated with Outcome in Patients with Coronary Artery Disease and Left Ventricular Dysfunction: Results of the Genetic Substudy of the Surgical Treatment for Ischemic Heart Failure (STICH) Trials. Cardiology, 2015, 130, 69-81.	1.4	4
63	Restoring public trust in scientific research by reducing conflicts of interest. Journal of Clinical Investigation, 2019, 129, 3971-3973.	8.2	4
64	Publishing â€œInvisibleâ€•and â€œAbandonedâ€•Clinical Trials: A Commitment for CTS. Clinical and Translational Science, 2013, 6, 251-253.	3.1	3
65	An observational preâ€"post study of re-structuring Medicine inpatient teaching service: Improved continuity of care within constraint of 2011 duty hours. Healthcare, 2015, 3, 129-134.	1.3	3
66	The Development of Î²-Adrenergic Receptor Antagonists for the Treatment of Heart Failure: A Paradigm for Translational Science. Circulation Research, 2011, 109, 1173-1175.	4.5	2
67	On Being a Chair of Medicine in 2012. American Journal of Medicine, 2012, 125, 315-319.	1.5	2
68	Publishing Genomic Studies: Walking the Fine Line. Clinical and Translational Science, 2012, 5, 1-2.	3.1	2
69	The Bayh-Dole Act, A Lion without Claws. Clinical and Translational Science, 2015, 8, 3-4.	3.1	2
70	Academic Medical Centers: Too Big to Fail. Clinical and Translational Science, 2013, 6, 419-420.	3.1	1
71	Clinical and Translational Science (CTS): 2005â€"2015. Clinical and Translational Science, 2015, 8, 621-622.	3.1	1
72	Undergraduate medical education in the U.S. and Israel: contrasts and common challenges. Israel Journal of Health Policy Research, 2015, 4, 56.	2.6	1

#	Article	IF	Citations
73	Ivabradine in Cardiovascular Disease. Journal of Cardiovascular Pharmacology, 2015, 65, 549-551.	1.9	1
74	Precision Medicine for Heart Failure. Journal of the American College of Cardiology, 2019, 73, 1185-1188.	2.8	1
75	Federal Politics and the Clinical and Translational Sciences. Clinical and Translational Science, 2011, 4, 395-396.	3.1	0
76	Mixing Politics and Medicine: A Case Study. Clinical and Translational Science, 2014, 7, 351-353.	3.1	0
77	Response to â€œClarification of Enrolled Subjects in Tolvaptan HF Trialsâ€ Clinical Pharmacology and Therapeutics, 2014, 96, 661-661.	4.7	0
78	An Opportunity to Definitively Evaluate the Theoretical Risks of Neprilysin Inhibition. JACC: Heart Failure, 2017, 5, 851-852.	4.1	0
79	The Heart-Brain Continuum: A New Way of Looking at Heart Failure Therapy. Journal of Cardiac Failure, 2018, 24, 537-539.	1.7	0
80	Letter by Feldman et al Regarding Article, â€œPhenotypic Refinement of Heart Failure in a National Biobank Facilitates Genetic Discoveryâ€ Circulation, 2019, 140, e5-e6.	1.6	0